Professor, The Saul R. Korey Department of Neurology
Our laboratory applies a variety of neurophysiologic techniques to explore normal and altered function in animal models and human clinical research. Experimental procedures include EEG, evoked potentials, ensemble and single unit recordings, current source density, and measures of whole nerve conduction velocity. Recently we have focused on developing sensitive biomarkers for the onset and progression of toxic neuropathies and seizure disorders. We have studied transgenic and mutant mice, models of diabetic neuropathy, compound-induced seizures, and demyelinating and iatrogenic deficits of central and peripheral nerve function. In parallel, we have participated in the “translation” of basic neuroscience principles to human clinical studies. We are currently involved in the design and conduct of multicenter Phase 1-4 clinical trials of experimental therapies intended to reduce or prevent diabetic and chemotherapy-induced neuropathies, to improve the treatment of chronic inflammatory demyelinating polyneuropathy, to explore treatment for ALS, and to monitor the modulation of pain. In this latter capacity, we have worked with the Centers for Disease Prevention and Control, the Environmental Protection Agency, the National Institute of Occupational Safety and Health and numerous pharmaceutical and biotechnology companies.
Antoine, M.W., Hübner, C.A., Arezzo, J.C. and Hébert, J.M. A causative link between innerear defects and long-term striatal dysfunction, Science, in press.
Arezzo, J.C., Seto, S. and Schaumburg, H.H. Sensory-Motor Assessment in ClinicalResearch Trials. Handbook of Clinical Neurology, Vol. 115, (3rd series) Peripheral Nerve Disorders, In: G. Said and C. Kraup, (Eds.), 2013.
Zotova, E.G. Arezzo, J.C. Non-invasive evaluation of nerve conduction in small diameterfibers in the rat. Physiology Journal, Article ID 254789, 2013.
Arezzo, J.C., Litwak, M, and Zotova, E. Correlation and Dissociation of Electrophysiology andHistopathology in the Assessment of
Toxic Neuropathy. Toxicologic Pathology 39:14651, 2011.
Foster, W.R. Car, B.D., Shi, H, Levesque, .PC., Obemeier M.T., Gan, J., Arezzo, J.C. et al.,Drug safety is a barrier to the discovery
and development of new androgen receptoantagonist. Prostate 5:4808, 2011.
Dyck, P.J., Albers. J.W., Andersen, H., Arezzo, J.C., Biessels, G.J., Bril, V., Feldman, E.L.,Litchy, W.J., O’Brien, P.C. and Russell,
J.W. Diabetic polyneuropathies: Update on research definitions, diagnostic criteria and estimation of severity. Diabetes Metab Res
Swain, S.M. and Arezzo, J.C. Neuropathy associated with microtubule inhibitors: Diagnosis incidence and management. Clinical
Advances in Hematology & Oncology,6(6):45546, 2008.
Zotova, E.G., Schaumburg, H.H., Raine, C.S., Cannella, B., Tar, M., Melman, A and Arezzo, J.C. Effects of hyperglycemia on rat
cavernous nerve axons: a functional and ultrastructural study, Experimental Neurology 213:439447, 2008.
Arezzo, J.C., Rosenstock, J. LaMoreaue, L. and Pauer, L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic
peripheral neuropathy. BMC Neurology 8:33, 2008.
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.
Albert Einstein College of Medicine
Rose F. Kennedy Center
1410 Pelham Parkway South , Room 322
Bronx, NY 10461